Phase II study of first-line treatment of HP + advanced gastric cancer withCamrelizumab for Injection plus SOX versus SOX

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100041935

Enrollment

Unknown

Registered

2021-01-10

Start date

2021-01-05

Completion date

Unknown

Last updated

2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stomach cancer

Interventions

Camrelizumab plus SOX group:Nil

SOX group:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Collect more than 30 patients diagnosed with advanced gastric cancer in our hospital from January 2020 to December 2021; 2. Patients with stage IV gastric cancer diagnosed by pathology and the HP test was positive; 3. PS score 2-3, able Received combined chemotherapy; 4. There are measurable lesions and distant metastatic lesions; 5. The liver and kidney functions are normal; 6. The patient and family members agree and sign the consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of hypertension, coronary heart disease, and abnormal heart function; 2. Patients with grade 3/4 hematological or non-hematological adverse reactions after taking the first course of medication for less than 2 weeks; 3. Patients who fail to review and evaluate regularly as required.

Design outcomes

Primary

Measure	Time frame
PFS;	—

Secondary

Measure	Time frame
OS;AE;	—

Countries

China

Contacts

Public ContactYunqi Hua

Baotou Cancer Hospital

hyqyfr@126.com+86 13015056119

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026